SLx-2119(KD-025,Belumosudil ) Datasheet | DC8329

SLx-2119(KD-025,Belumosudil ) — Datasheet

CAT. NO. DC8329

Parameter	Value
Chemical Name	SLx-2119
CAS No.	911417-87-3
Synonyms	SLx2119(KD025)，SLx 2119(KD 025)，SLx2119，KD025
Formula	C26H24N6O2
M.Wt	452.518
SMILES	O=C(C([H])([H])OC1=C([H])C([H])=C([H])C(C2=NC3=C([H])C([H])=C([H])C([H])=C3C(N([H])C(C([H])=C4[H])=C([H])C5=C4N([H])N=C5[H])=N2)=C1[H])N([H])C(C([H])([H])[H])([H])C([H])([H])[H]
Purity	>98%
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

SLx-2119 is a selective inhibitor of ROCK2 with an IC50 of 105 nM.

In Vitro

SLx-2119 (40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays[1].

In Vivo

KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males[2].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

SLx-2119(KD-025,Belumosudil ) — Datasheet

Biological Activity

In Vitro

In Vivo

References & source

Cart